Welcome to our dedicated page for Imagin Medical news (Ticker: IMEXF), a resource for investors and traders seeking the latest updates and insights on Imagin Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Imagin Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Imagin Medical's position in the market.
Imagin Medical has chosen Lighthouse Imaging as the contract manufacturer for its i/Blue Imaging System, a significant advancement towards market approval. Founded in 1984, Lighthouse specializes in FDA-approved medical devices and will assist in the development of Imagin's minimally invasive imaging technology. CEO Jim Hutchens emphasized the importance of this partnership in meeting FDA requirements. The i/Blue system aims to improve cancer visualization during procedures, primarily targeting bladder cancer, thus enhancing detection accuracy and efficiency.
Imagin Medical announced a virtual investor event on October 29, 2020, at 12:00 pm EDT, featuring Key Opinion Leaders discussing the i/Blue™ Imaging System. The event aims to showcase advancements in bladder cancer imaging, addressing the pressing need for improved methods to reduce recurrence and mortality rates. CEO Jim Hutchens emphasized the importance of this technology for detecting cancer during minimally invasive surgeries. The webcast will be accessible live and archived via the Company's website.
Imagin Medical (CSE:IME, OTCQB:IMEXF) reported its fiscal 2020 third-quarter results on August 28, 2020. Total operating expenses decreased to $582,755 from $1,133,901 in 2019, driven by lower R&D and G&A costs. R&D expenses amounted to $235,656, down from $659,836, primarily due to strategic outsourcing. The net loss for the quarter was $582,805, consistent with a $0.01 loss per share, albeit improved from the previous year's loss of $1,201,561. As of June 30, 2020, the company had $269,205 in cash and 178,340,278 shares outstanding, indicating a focus on extending its cash runway amid the pandemic.
FAQ
What is the market cap of Imagin Medical (IMEXF)?
